** Shares of CSPC Pharmaceutical Group 1093.HK jump 9.2% to HK$9.99, on course for biggest one-day pct gain since June 6

** Stock on track to snap two straight sessions of falls

** CSPC says its product Clevidipine Injectable Emulsion for treatment of hypertension has obtained drug registration approval from China's National Medical Products Administration

** Says approval will enrich its product pipeline in the therapeutic area of cardiovascular disease, enhance its competitiveness while addressing clinical needs for medications used in hypertensive emergencies

** YTD, stock up 17.3%, Hang Seng Biotech Index .HSBIO up 6.4%

(Reporting by Donny Kwok)

((donny.kwok@thomsonreuters.com))